NACDS Foundation announces election results
ALEXANDRIA, Va. The National Association of Chain Drug Stores Foundation elected officers on April 28 during its annual meeting. Additionally, five new members joined the board of directors, and eighteen current members were re-elected.
Among its activities, the Foundation provides scholarships for pharmacy students and supports pharmacy education programs that address the needs of community pharmacy practice. Additionally, the Foundation supports research efforts, which document community pharmacy’s role and value in America’s healthcare system.
The newly elected members were:
- Charles Burnett, senior vice president, pharmacy, Costco Wholesale and Costco Pharmacies
- Lynn Campbell, director, shopper marketing—drug, club, mass and military, Coca-Cola
- Art Drogue, senior vice president, U.S. customer development, Unilever
- Paul McGarty, chief executive officer, Fougera
- Tammy McIntire, president, Apotex
Elected as Foundation board officers were:
- Chairman: Steve Anderson, NACDS president and chief executive officer
- Phillip Schneider, president, NACDS Foundation, and vice president, NACDS external affairs
- Secretary: Sandra Guckian, NACDS, vice president, pharmacy education and research
- Treasurer: R. James Huber, NACDS, executive vice president, finance and administration, and chief financial officer
The re-elected board members were:
- Robert W. Belknap, Jr., executive director, trade sales and operations, Boehringer Ingelheim Pharmaceuticals
- James Caro, senior director, pharmacy practice and trade organizations, Sanofi-Aventis
- Anthony Civello, chairman, president and chief executive officer, Kerr Drug
- Eileen Dunn, vice president, corporate communications and community relations, CVS Caremark
- John Fish, vice president, channel management and pharmacy solutions, GlaxoSmithKline
- Phillip Gioia, senior vice president generic sales and marketing, Barr Laboratories
- Mark Griffin, president and chief executive officer, Lewis Drugs
- Robert James Mauro, chief executive officer, Amerigen Pharmaceuticals
- Karl Obrecht, executive vice president, customer business development, Revlon
- Stephen Paoletti, senior vice president, customer development, Hallmark Cards
- Theresa Parker, director, trade relations and pharmacy development, Abbott—Pharmaceutical products division
- Karen Rugen, senior vice president, corporate communications and public affairs, Rite Aid
- Bryan Stuke, vice president, customer business development, Procter & Gamble
- Kevin Tripp, executive vice president and president, retail Midwest, Supervalu
Hormone deemed effective in male birth-control pill
TORRANCE, Calif. According to published reports, one of the two government-funded research centers in the U.S. for male contraceptives has discovered hormone pills that block sperm production in men and has found them to be safe and reversible.
The hormone combination that proved most successful halts testosterone production in the testicles, but fakes the body into believing that testosterone levels are the same, according to the study. The progestin, typically a female hormone, speeds the process and improves the effectiveness of the drug, research shows. The hormones can be taken in a pill or injection form.
As with female birth control, the male contraceptives don’t prevent sexually transmitted disease. But they have proven as effective as female pills in preventing pregnancy, according to the study.
The next goal is to find pharmaceutical companies that want to conduct final development of the drug, but so far companies have been unwillingly to take part because of the regulatory requirement involved in manufacturing a contraceptive.
Federal appeals court lets Washington state Plan B ruling stand
LOS ANGELES A federal appeals court on Thursday left in place a lower court’s ruling that allowed Washington state pharmacists to refuse to sell Duramed’s emergency contraceptive pill Plan B on religious grounds, according to Reuters.
A federal judge in Seattle suspended state rules that required pharmacies to dispense the drug and other emergency contraceptives that prevent fertilized eggs from implanting, which some people believe is the same as abortion.
U.S. District Judge Ronald Leighton found that the state rules force pharmacists into an unconstitutional choice between their religious beliefs and their work.
State officials and several women had asked the Ninth U.S. Circuit Court of Appeals to suspend the judge’s preliminary injunction, which bars them from enforcing the law, while they appeal his ruling.
In a split decision, the appeals court denied that request, finding that the state and the women did not show that they would suffer irreparable harm if the injunction stayed in place pending the appeal.